Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-627 vs GRAN for Chemotherapy-Induced Neutropenia in Breast Cancer
NCT04174599Phase 3Completed
- Sponsor
- Evive Biotech
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of efbemalenograstim alfa in neutropenia (2 arms), sponsored by Evive Biotech. Primary endpoint: Duration of Grade 3 or 4 Neutropenia in Cycle 1. Started Apr 2018; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT04174599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04174599.